> top > docs > PMC:7029759 > spans > 20538-22069 > annotations

PMC:7029759 / 20538-22069 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
468 81-85 Gene denotes ACE2 Gene:59272
469 247-251 Gene denotes ACE2 Gene:59272
470 470-474 Gene denotes ACE2 Gene:59272
471 649-653 Gene denotes ACE2 Gene:59272
472 819-823 Gene denotes ACE2 Gene:59272
473 1238-1242 Gene denotes scFv Gene:652070
474 1258-1262 Gene denotes ACE2 Gene:59272
475 996-1005 Species denotes mammalian Tax:9606
476 1128-1136 Species denotes patients Tax:9606
477 114-133 Disease denotes 2019-nCoV infection MESH:C000657245
478 192-196 Disease denotes SARS MESH:D045169
479 754-766 Disease denotes inflammation MESH:D007249

LitCovid-PMC-OGER-BB

Id Subject Object Predicate Lexical cue
T357 53-61 GO:0042571 denotes antibody
T356 81-85 G_3;PG_10;PR:000003622 denotes ACE2
T355 114-123 SP_7 denotes 2019-nCoV
T354 192-196 SP_10 denotes SARS
T353 207-218 GO:0006260 denotes replication
T352 247-251 G_3;PG_10;PR:000003622 denotes ACE2
T351 252-260 GO:0042571 denotes antibody
T350 319-329 GO:0042571 denotes antibodies
T349 449-454 NCBITaxon:10239 denotes viral
T348 470-474 G_3;PG_10;PR:000003622 denotes ACE2
T347 483-491 GO:0042571 denotes antibody
T346 556-565 PG_1 denotes S protein
T345 649-653 G_3;PG_10;PR:000003622 denotes ACE2
T344 654-662 GO:0042571 denotes antibody
T343 677-685 CHEBI:35224;CHEBI:35224 denotes effector
T342 733-739 SO:0000417 denotes domain
T341 800-807 UBERON:0000479 denotes tissues
T340 808-818 GO:0010467 denotes expressing
T339 819-823 G_3;PG_10;PR:000003622 denotes ACE2
T338 880-886 SO:0000417 denotes domain
T337 953-959 SO:0000417 denotes domain
T336 996-1005 NCBITaxon:40674 denotes mammalian
T335 1006-1021 GO:0006412 denotes cell production
T334 1120-1124 CHEBI:23888;CHEBI:23888 denotes drug
T333 1258-1262 G_3;PG_10;PR:000003622 denotes ACE2
T332 1282-1289 SO:0000417 denotes domains
T331 1366-1374 NCBITaxon:2 denotes bacteria
T330 1443-1450 UBERON:0000479 denotes tissues
T329 1499-1508 CHEBI:36357;CHEBI:36357 denotes molecules
T328 1524-1530 SO:0000417 denotes domain

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T117 53-61 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T118 86-93 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T119 252-260 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T120 483-491 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T121 558-565 Body_part denotes protein http://purl.org/sig/ont/fma/fma67257
T122 654-662 Body_part denotes antibody http://purl.org/sig/ont/fma/fma62871
T123 800-807 Body_part denotes tissues http://purl.org/sig/ont/fma/fma9637
T124 1006-1010 Body_part denotes cell http://purl.org/sig/ont/fma/fma68646
T125 1443-1450 Body_part denotes tissues http://purl.org/sig/ont/fma/fma9637

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T60 114-133 Disease denotes 2019-nCoV infection http://purl.obolibrary.org/obo/MONDO_0100096
T61 124-133 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T62 192-196 Disease denotes SARS http://purl.obolibrary.org/obo/MONDO_0005091
T63 754-766 Disease denotes inflammation http://purl.obolibrary.org/obo/MONDO_0021166

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T178 0-1 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T179 358-367 http://purl.obolibrary.org/obo/CLO_0036932 denotes hybridoma
T180 397-398 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T181 577-578 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T182 730-732 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T183 877-879 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T184 950-952 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc
T185 979-980 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T186 1006-1010 http://purl.obolibrary.org/obo/GO_0005623 denotes cell
T187 1204-1205 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T188 1264-1265 http://purl.obolibrary.org/obo/CLO_0001020 denotes A
T189 1366-1374 http://purl.obolibrary.org/obo/NCBITaxon_2 denotes bacteria
T190 1521-1523 http://purl.obolibrary.org/obo/CLO_0052676 denotes Fc

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T78 86-93 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T79 558-565 Chemical denotes protein http://purl.obolibrary.org/obo/CHEBI_36080
T80 677-685 Chemical denotes effector http://purl.obolibrary.org/obo/CHEBI_35224
T81 1120-1124 Chemical denotes drug http://purl.obolibrary.org/obo/CHEBI_23888
T82 1499-1508 Chemical denotes molecules http://purl.obolibrary.org/obo/CHEBI_25367

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T12 754-766 http://purl.obolibrary.org/obo/GO_0006954 denotes inflammation
T13 1048-1061 http://purl.obolibrary.org/obo/GO_0070085 denotes glycosylation

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T131 0-146 Sentence denotes A second, similar strategy would be to administer an antibody that would bind to ACE2 protein, thereby preventing 2019-nCoV infection ( Figure 1).
T132 147-237 Sentence denotes This strategy was shown to effectively block SARS entry and replication in experiments 42.
T133 238-414 Sentence denotes While no ACE2 antibody sequences are published in literature indexes, monoclonal antibodies do exist and the associated hybridoma sequences could be cloned in a matter of days.
T134 415-566 Sentence denotes There would be no concern for any viral escape from an ACE2 binding antibody, which is an advantage over neutralizing approaches against the S protein.
T135 567-672 Sentence denotes There are a couple of design considerations when thinking about how to employ the ACE2 antibody strategy.
T136 673-824 Sentence denotes Any effector functions would need to be removed from the Fc domain 49, such that inflammation would not be caused in different tissues expressing ACE2.
T137 825-919 Sentence denotes This would retain the long-half life endowed by the Fc domain without any of the side effects.
T138 920-1162 Sentence denotes The downside of including the Fc domain is the need to use a more expensive mammalian cell production system to preserve proper glycosylation, which would decrease the turnaround time for getting the drug to patients in the outbreak scenario.
T139 1163-1263 Sentence denotes Alternatively, one could just administer a single chain variable fragment (scFv) that binds to ACE2.
T140 1264-1338 Sentence denotes A nanobody or VHH domains from camelids are another option as well 50, 51.
T141 1339-1451 Sentence denotes These could be produced in bacteria, and its small size would allow for rapid permeation into different tissues.
T142 1452-1531 Sentence denotes The downside is the shorter half-life of these molecules without the Fc domain.